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Innovative vaccine platforms are needed to develop effective countermeasures against emerging and
re-emerging diseases. These platforms should direct antigen internalization by antigen presenting cells and
promote immunogenic responses. This work describes an innovative systems approach combining two
novel platforms, aGalactose (aGal)-modification of antigens and amphiphilic polyanhydride nanoparticles
as vaccine delivery vehicles, to rationally design vaccine formulations. Regimens comprising soluble
aGal-modified antigen and nanoparticle-encapsulated unmodified antigen induced a high titer, high avidity
antibody response with broader epitope recognition of antigenic peptides than other regimen. Proliferation
of antigen-specific CD41 T cells was also enhanced compared to a traditional adjuvant. Combining the
technology platforms and augmenting immune response studies with peptide arrays and informatics
analysis provides a new paradigm for rational, systems-based design of next generation vaccine platforms
against emerging and re-emerging pathogens.
M
edical needs have changed considerably in the 21st century due, in part, to the fact that many pathogens
have evolved to evade the host immune response. This evolution has rendered current vaccine strategies
inadequate for providing protection against emerging and re-emerging infections. Efficient priming of
the immune system is required for the induction of robust immune responses. Current vaccines are often less
immunostimulatory because soluble doses of antigens are rapidly cleared and poorly immunogenic. Chemical
modification of antigens that would target immune cells and/or increase their recognition by immune cells would
be important for the induction of protective immunity. Another approach to efficiently prime the immune system
is to use adjuvants1. Ideally, adjuvants will also function as delivery platforms that can release stable immunogens
to antigen presenting cells (APCs) upon immunization. The sustained release of antigen provides for longer and
efficient antigen dosing and may ultimately lead to development of single dose vaccines2. Conventional
approaches in vaccine design in which antigens and off-the-shelf adjuvants are ‘‘mixed and matched,’’ have
proven to be inefficient. In order to rationally design vaccines and make transformative improvements in vaccine
efficacy, it is important to concomitantly design both the antigen and the adjuvant. This work describes a novel
systems approach in which the advantage of judiciously combining antigens and nanoscale adjuvants results in
the induction of robust immune responses.
Biodegradable polymer-based nanoparticle platforms have been studied extensively for vaccine delivery;
specifically, polyanhydride particles possess intrinsic adjuvant properties and have demonstrated the ability to
provide sustained release of protein antigens, activate APCs, andmodulate the immune response3–12. We recently
demonstrated the ability of a rationally-designed nanovaccine based on the antigen, F1-V, and amphiphilic
nanoparticles composed of 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-diox-
aoctane (CPTEG) to induce long-lived protection (i.e., 280 days after a single intranasal dose) against plague in
mice upon lethal challenge with Yersinia pestis11,12.
OPEN
SUBJECT AREAS:
PRE-CLINICAL STUDIES
BIOMATERIALS - VACCINES
Received
9 July 2013
Accepted
20 December 2013
Published
20 January 2014
Correspondence and
requests for materials
should be addressed to
B.N. (nbalaji@iastate.
edu) or M.J.W.
(mjwannem@iastate.
edu)
* These authors
contributed equally to
this work.
{Current address:
Boehringer Ingelheim,
Ames, IA 50010.
SCIENTIFIC REPORTS | 4 : 3775 | DOI: 10.1038/srep03775 1
In this work, we exploit the presence of naturally occurring serum
antibody to aGal in order to enhance the humoral response to F1-V,
a fusion protein that has been previously utilized as an immunogen in
Y. pestis vaccines13. This was accomplished by haptenating F1-Vwith
aGal epitopes [galactose-alpha(1,3)-galactose-beta(1,4)N-acetylglu-
cosamine-R (Gal-a(1,3)-Gal-b(1,4)-GlcNAc-R)]. This approach
takes advantage of the absence of a-1,3 galactosyl transferase genes
in humans who, therefore, are unable to functionally glycosylate
proteins and glycolipids with aGal epitopes14,15. Consequently,
aGal epitopes found on bacteria and foods are recognized as foreign
resulting in the generation of serum anti-aGal antibodies that rep-
resent more than 1% of total serum IgG14,15. These anti-aGal anti-
bodies can be exploited to target and enhance the interaction of
immune complexes (ICs) to follicular dendritic cells and B cells16–18.
aGal modification has been shown to substantially increase the
immunogenicity of proteins as diverse as bovine serum albumin19
and HIV gp12018.
Herein, we describe a systems approach by combining aGal modi-
fication of F1-V with the amphiphilic polyanhydride nanovaccine
platform to rationally design a next generation vaccine against Y.
pestis. We hypothesize that a systems approach would synergistically
augment and accelerate an antigen-specific immune response that
recognizes a broader repertoire of antigenic epitopes and allows for
the development of a single-dose vaccine that reduces the need for
multiple injections. Vaccine formulations composed of these tech-
nology platforms were tested in an a1, 3 galactosyltransferase
(a1,3GT) gene knockout (KO) mouse model, which lacks aGal epi-
topes and can produce high-titer anti-aGal antibodies similar to
humans, thereby mimicking human immune characteristics20.
Results
Soluble aGal-F1-V and unmodified F1-V encapsulated within
nanoparticles (SaGal 1 Eunmod) synergistically generated a high
titer, high avidity antibody response. We hypothesized that
vaccine formulations consisting of soluble and nanoparticle-
encapsulated protein would induce high titer serum antibody,
which is generally required to induce protection against several
diseases, including plague21–23. To test this hypothesis, mice were
vaccinated subcutaneously with the vaccine formulations shown in
Table 1 and then subcutaneously boosted with 5 mg of unmodified
F1-V antigen 37 days after the primary vaccination. Monophos-
phoryl lipid A (MPLA) is a vaccine adjuvant that has been
approved for use in humans by the U.S. Food and Drug
Administration (FDA) and was used as a control adjuvant in these
studies. Anti-F1-V antibody titers were evaluated pre-boost (day 36)
and post-boost (day 42).
The vaccine regimen comprised of soluble aGal-F1-V and nano-
particles encapsulating unmodified F1-V (SaGal 1 Eunmod) elicited a
high titer, high avidity antibody response against F1-V (Figure 1).
Immunizing mice with only unmodified antigen encapsulated in
50550 CPTEG5CPH nanoparticles (i.e., no soluble dose) generated
low (,1,000) antibody titers (data not shown). These data indicate
that a combination of nanoparticle-encapsulated and soluble antigen
is critical for the induction of high antibody titers after a primary
immunization, which is consistent with previous work11. Following
an antigenic boost at day 36, all the immunized mice, independent of
the vaccine regimen used, responded robustly indicating that they
were immunologically primed (Figure 1A).
Because an immune response against the LcrV protein (V antigen)
is critical for protection against plague13,24,25, ELISAs were performed
to determine if antibodies produced after immunization with the
selected vaccine regimens were specific for the V antigen. All the
vaccine formulations evaluated induced similar levels of anti-LcrV
antibodies with the exception of the nanoparticle-encapsulated
unmodified F1-V group (Eunmod), for which the average titer value
was below 1,000 (data not shown).
In addition to the quantitative humoral response, antibody quality
plays an important role in mounting a protective response against
pathogens such as Y. pestis11 and Streptococcus pneumoniae26. As a
measure of quality, antibody avidity was evaluated by assessing bind-
ing in the presence of the chaotropic reagent, sodium thiocyanate.
Prior to the booster immunization, mice immunized with SaGal 1
Eunmod produced antibodies with high avidity (Figure 1B). Following
the booster immunization, the antibody avidity of all immunized
mice was significantly enhanced (Figure 1B) with the exception of
those receiving the MPLA 1 SaGal formulation, which already had
high avidity antibodies. Moreover, mice immunized with regimens
containing aGal-F1-V alone or in conjunction with nanoparticles
presented with significantly higher avidity antibodies as compared
to antibody from mice immunized with the unmodified F1-V.
Soluble aGal-F1-V 1 F1-V encapsulated nanoparticles (SaGal 1
Eunmod) promoted the development of antigen-specific CD41 T
cell responses. Although humoral immunity is required for protec-
tion against plague, evidence suggests that cell-mediated immunity
may also be necessary27,28. Indeed, CD41 T helper cells provide B cell
help at various stages of the humoral immune response29,30. To
investigate if our vaccine formulations induced a T cell response,
antigen-specific CD41 T cell proliferation was evaluated via an in
vitro recall response. Significantly more antigen-specific T cell proli-
feration was observed in cultures of lymph node cells recovered from
mice vaccinated with the SaGal 1 Eunmod formulation as compared to
cultures of lymph node cells isolated frommice immunized with any
other formulation (Figure 2). CD41 T cells from mice immunized
with either SaGal or Sunmod F1-V antigen adjuvanted with MPLA
showed no significant increase in proliferation over those from
saline controls. Similarly, no difference in recall response was
observed for lymph node cells recovered from mice immunized
with nanoparticle-encapsulated unmodified (SI 5 2.11) or aGal-
modified (SI 5 1.17) F1-V (data not shown) compared to naı¨ve
controls. Of note, the only other vaccine formulation to induce
significantly more antigen-specific proliferative CD41 T cells as
compared to naı¨ve control mice was the SaGal alone.
Immunization with the SaGal1 Eunmod formulation generated anti-
bodies that were more broadly reactive to F1-V peptide epitopes.
Many pathogens evade immune system recognition and clearance by
eliciting antibody responses against non-protective epitopes or by
constantly mutating their antibody binding sites to avoid inhibition
via antibodies raised against previous strains. Designing vaccine
formulations capable of generating broadly reactive antibodies
would prevent pathogen escape and reduce the risk of pandemic
spread. To characterize the breadth of the serum antibody reactivity
to specific F1-V protein epitopes following vaccination, we examined
Table 1 | Vaccination regimens
Group # Experimental Group
Soluble
F1-V (mg)*
Soluble aGal-
F1-V (mg)*
Encapsulated
F1-V (mg)*
1 Control-Saline --- -- - -- -- - - -- -
2 Sunmod 5 --- -- - - -- -
3 SaGal --- -- 5 ---- -
4 Sunmod 1 Eunmod 2.5 --- -- 2.5
5 SaGal 1 Eunmod --- -- 2.5 2.5
6 Sunmod 1 MPLA 5 ----- - - -- -
7 SaGal 1 MPLA ----- 5 ---- -
*Quantities indicate the amounts of immunogen delivered to each mouse in the indicated group. S
5 soluble antigen; E 5 encapsulated antigen. Subscripts indicate type of F1-V antigen (i.e.,
unmodified or aGal-modified F1-V) administered per dose. Each mouse was administered 500 mg
of 50550 CPTEG5CPH nanoparticles or 10 mg of MPLA in respective treatment formulations. All
formulations were administered subcutaneously in a total volume of 100 mL of saline. Following
primary immunization with the various vaccine formulations, the mice were then subcutaneously
administered with a booster immunization at day 37, comprising 5 mg of unmodified F1-V.
www.nature.com/scientificreports
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antibody binding against two separate panels of overlapping peptides.
The first panel of 27 peptides covered the full length of the F1 antigen
and the second panel covered the full length of the V antigen (53
peptides). Hierarchical clustering analysis and principal component
analysis (PCA) of the generated data matrix enabled identification of
immunodominant peptides (Figures 3A and 3B). Of the 27 F1
peptides evaluated, only two (i.e., F1-1 and F1-18) were recognized
by sera from all immunized mice. Consistent with previous findings31,
the majority of the anti-F1-V response was directed against the V
portion of the protein and, in particular, against six V peptides (i.e.,
V-2, V-14, V-19, V-20, V-27 and V-44) (Figures 3A and 3B). Of note,
removal of these dominant peptides from the data analysis revealed
widespread recognition of multiple F1 and V peptides by serum
antibodies from mice immunized with the SaGal 1 Eunmod formu-
lation (Figure 3C, lane 5). In contrast, serum antibodies from mice
immunized with F1-V 1 MPLA showed weak reactivity to the vast
majority of the remaining F1-V peptides, indicating that most of the
antibodies were directed against the immunodominant epitopes.
The peptide region spanning amino acids 196–225 of LcrV is
known to be protective in mice31,32. Six of the V peptides in the array,
V-32, V-33, V-34, V-35, V-36 andV-37, are located in this region. To
evaluate the antibody response in the protective region of the V
protein, we evaluated the increase in antibody reactivity over saline
controls for these six peptides. Once again, the antibodies frommice
immunized with the SaGal 1 Eunmod formulation demonstrated the
greatest recognition with at least a 1.5-fold change for five (i.e., V-32,
33, 35, 36 and 37) of the six peptides (Figure 3D). In contrast, anti-
bodies from the SaGal 1 MPLA group reacted strongly with only the
V-33 peptide, while the Sunmod 1 MPLA group showed a 1.5-fold
change for only two peptides.
Identification of the lead candidate nanovaccine formulation. PCA
was used to perform a composite analysis of the immune response
data, including the antibody responses, T cell proliferation, and
peptide array data (Supplementary Fig. 3). This analysis enabled
simultaneous investigation of the relationships among the multiple
variables of the vaccine regimens evaluated in this study, including
aGal modification of the F1-V, use of nanoparticles versusMPLA, and
amount of soluble versus nanoparticle-encapsulated protein.
Figure 4 shows the results from the PCA. In this figure, the dis-
tance along the direction (i.e., down and to the right) of the red arrow
indicates enhancement in immunity compared to the saline treat-
ment. Treatments circled together in blue demonstrated similar res-
ponses. When the unmodified F1-V antigen was delivered as either
soluble protein alone (Sunmod) or together with nanoparticles (Sunmod
1 Eunmod), the groups were located closer to the saline control in the
principal component data space, indicating that the weakest immune
response was obtained after vaccination with these regimens. The
analysis also indicated that the impact of adding MPLA as an adjuv-
ant is unclear. While adding MPLA to either Sunmod or SaGal
increased the distance from the saline control along the PC1 axis,
both formulations were located in the top quadrant, indicating sim-
ilarity to the saline control. The presence of soluble aGal-modified
F1-V in the vaccine formulation had the largest impact in terms of
significant change from the saline control because the SaGal and SaGal
1 Eunmod groups were located in the lower right quadrant.
Figure 1 | Soluble aGal-F1-V and F1-V encapsulated nanoparticle formulations synergistically generated a high titer, high avidity antibody response.
Mice were subcutaneously immunized with various vaccine formulations and then subcutaneously administered a boost of 5 mg of unmodified F1-V 37
days after immunization. Serumwas collected both prior to boost on day 36 (open bar) and after the boost (closed bar) at day 42 and evaluated for (A) F1-
V-specific antibody titers via ELISA measuring IgG (H 1 L) or (B) F1-V-specific antibody avidity using sodium thiocyanate as the chaotropic agent.
Data are presented as themean6 SEMof four independent experiments each consisting of 6–10mice per group. Letters represent statistical comparisons
among groups either pre-boost (smaller case) or post-boost (upper case). Treatments identified with different letters are significantly different from
one another (p # 0.05).
www.nature.com/scientificreports
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Ultimately, the analysis revealed that SaGal 1 Eunmod was the lead
candidate nanovaccine formulation based on its geometric distance
from the saline control along the red arrow.
Discussion
Efficacious vaccines capable of inducing protection against infectious
diseases are typically able to do so by mimicking the way in which a
naturally occurring infection induces a robust immune response7,33.
Directing antigen internalization by APCs and sustaining antigen
exposure are key elements to augmenting and extending immune
stimulation33,34. In this work, a systems approach is presented for the
rational design of efficacious vaccines by synergistically combining
two platforms, aGal modification of the vaccine antigen and amphi-
philic nanoparticles with dual functions as vaccine carriers and adju-
vants. Informatics analysis validated the synergy provided by this
approach by unraveling hidden relationships among multi-dimen-
sional attributes embedded in diverse sets of experimental data and
identifying a lead candidate nanovaccine formulation. The use of this
systems approach incorporated a holistic vaccine design philosophy
by focusing onmore than antibody titer (i.e., titer, avidity, breadth of
epitope recognition, and CD4 T cell reactivity) and enabled the iden-
tification of a formulation that generated a mature, high quality
humoral immune response as well as a cell-mediated immune
response.
In this work, we demonstrated that vaccine formulations contain-
ing soluble aGal-F1-V induced both a high-titer and high quality
antibody response (Figure 1A). The induction of endogenous high-
titer anti-aGal antibodies promotes opsonization of aGal-modified
antigens15,35 that would facilitate the formation of immune com-
plexes that would enhance antigen binding to follicular dendritic
cells (FDCs) for antigen presentation to B cells36,37 and antigen
uptake and presentation by APCs to enhance T cell responses via
several mechanisms, including complement activation and Fc recep-
tor (FcR)-mediated endocytosis16,18. Moreover, the formation of
these antigen-antibody immune complexes may potentially lead to
prolonged recycling of antigen on the surface of FDCs37, CD19/
CD21-mediated B cell activation38,39 and accelerated memory B cell
development, germinal center formation, and antibody affinity mat-
uration40,41. Despite an earlier report indicating that complement
receptors are not required for the development of antibody responses
following immunization with certain aGalmodified antigens19, more
recent work clearly demonstrates that other components of the
complement cascade are critical for antigen deposition on the surface
of FDCs, activation of germinal center B cells, and the subsequent
maturation of antigen-specific B cell response37,42,43. Long-term
retention of these immune complexes on FDCs and extended antigen
exposure to B cells are likely mechanisms by which complement and
preexisting antibody can contribute to productive primary and sec-
ondary B cell responses. Moreover, complement activation promotes
the release of various chemotactic factors that induce APCmigration
and uptake of aGal modified antigen by Fc receptor-mediated endo-
cytosis44,45. Collectively, these immune complex-mediated mechan-
isms may explain how our nanovaccines containing aGal-F1-V
induced a high-titer, high quality antibody response characterized
by a greater breadth of epitope recognition and F1-V-specific CD41
T cell responses when compared to vaccine regimen that did not
contain aGal-F1-V.
Antibody production was significantly enhanced when soluble
aGal-F1-V was delivered together with nanoparticle-encapsulated
unmodified F1-V (Figure 1A). This finding demonstrates the value
of the systems approach to vaccine design by effectively combining
the correct antigen and adjuvant platforms. Specifically, the efficacy
of including soluble aGal-modified antigen along with encapsulated
unmodified antigen may be attributable to the in situ generation of
F1-V immune complexes. Indeed, immune complexes are known to
significantly influence the rapidity, intensity, and specificity of the
subsequent antibody response against the target antigen40. The
enhanced immune effects promoted by immune complexes are
associated with affinity maturation of B cells41 and may result in
the production of more avid antibodies. This may explain why anti-
bodies with higher avidity were obtained following immunization
with aGal-modified F1-V (Figure 1B). In parallel, it is also known
that continuous antigen exposure is critical for developing high
avidity antibodies during affinity maturation46. In the present work,
antibodies with higher avidity were produced after immunization
with formulations containing both soluble and nanoparticle-encap-
sulated antigen (Figure 1B), demonstrating the role of the nanopar-
ticles in providing continual antigen release. Previous work from our
Figure 2 | Soluble aGal-F1-V combined with F1-V encapsulated nanoparticles promoted the development of antigen-specific CD41 T cell responses.
Draining lymph node cells were harvested at d42 post-immunization, labeled with CFSE, cultured with or without 10 mg/mL of F1-V antigen for four
days, stained with fluorescent antibodies against CD4, and analyzed by flow cytometry. Stimulation index was calculated by dividing the percentage of
CD41 T cells that proliferated in the presence of F1-V by the percentage of CD41 T cells that proliferated in the medium alone control. Data are
presented as the mean stimulation index 6 SEM of two independent experiments each consisting of 6–10 mice per treatment group. Treatments
identified with different letters are significantly different from one another (p # 0.05).
www.nature.com/scientificreports
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Figure 3 | Antibodies generated by immunization with the SaGal 1 Eunmod formulation were more broadly reactive to F1-V peptide epitopes.
Differential epitope recognition by antibodies elicited during immunization with the various vaccine formulations was determined using a peptide array
for both F1 and V antigens from Y. pestis. Mice were immunized with the vaccine regimens described in Table 1 and administered an antigenic boost of
5 mg of unmodified F1-V 37 days after immunization. (A) Heat map depicting recognition of the 80 peptides via mouse sera after hierarchical clustering
analysis implementation, which allows for grouping of peptides demonstrating a relatively higher response than others. (B) Principal component analysis
(PCA) of peptide arrays corroborates as outliers the same set of peptides identified by clustering analysis. The plot maps out high dimensional
correlations, permitting identification of significant responders from the peptide array data. (C) Broader peptide recognition by specific vaccination
groups is illustrated by a heat map, depicting antibody responses elicited via different vaccination regimens against the set of peptides not identified as
outliers by the clustering analysis. (D) The increase in antibody reactivity over saline controls was used to determine antibody response against the
protective region of the V protein (represented by peptides V-32, V-33, V-34, V-35, V-36 and V-37). For (A) and (C), peptides for which greater
immunoreactivity was observed for specific immunization groups are presented as red, yellow, or light blue while vaccination treatments are represented
by numbers identifying each of the columns for the heat map: 1) control, 2) Sunmod, 3) SaGal, 4) Sunmod 1 Eunmod, 5) SaGal 1 Eunmod, 6) Sunmod 1 MPLA,
and 7) SaGal 1 MPLA. Data are the average measurements for three pooled serum samples per vaccination group (each of the pools contained samples
from three or four mice).
www.nature.com/scientificreports
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laboratories has shown that amphiphilic 50550 CPTEG5CPH nano-
particles were internalized by APCs at a slower rate than hydro-
phobic CPH:SA nanoparticles7,12. Moreover, the amphiphilic
nanoparticles persisted longer after subcutaneous administration47.
This depot effect, in combination with slow antigen release due to
nanoparticle degradation, likely allows for the extended presence of
antigen in vivo and results in more avid antibodies.
In addition to enhancing antibody production, the SaGal 1 Eunmod
formulation also induced the greatest F1-V specific CD41 T cell
proliferation when compared to all other vaccine regimens used in
this study (Figure 2). This enhanced T cell response may be a con-
sequence of improved FcR-mediated uptake of aGal-F1-V immune
complexes and presentation via APCs. The cross-presentation path-
way accessed by antigens acquired endocytically through FcRs has
been previously reported to enhance antigen-specific T cell res-
ponses, thereby linking the preexisting anti-aGal antibody response
with enhanced cellular immunity48.
Preservation of antigenic epitopes during vaccine delivery is essen-
tial for generating a protective immune response31. In this regard, the
amphiphilic 50550 CPTEG5CPH particles have been shown prev-
iously to release stable F1-V antigen5, which may translate into epi-
tope preservation in vivo. Applying informatics analysis tools to
peptide array data of the F1-V protein revealed two F1 and six V
immunodominant peptides. An amino acid region that correlates
with protection from lethal challenge following passive immunother-
apy is located at the amino-terminal end of F123. It is well known that
the V antigen is an effector protein, and some of its epitopes are
important for activation of the contact-dependent Type III secretion
system during infection24,31,49–52. The LcrV region spanning amino
acids 135–27553, more specifically amino acids 196–22554, is the
dominant epitope for antibody-mediated protection against plague.
Here, we demonstrated that the SaGal 1 Eunmod vaccine formulation
not only elicited more avid antibodies specific for peptides encom-
passing the protective region (Figure 3D), but also elicited antibodies
recognizing amore diverse array of the remaining peptides, resulting
in a broader epitope spread. Previous work has shown that antigen-
antibody complexes may modulate the humoral immune response
by masking dominant epitopes, improving germinal center forma-
tion, inducing somatic hypermutations, and promoting changes in
antigen processing40. Furthermore, alterations in the sequences of T
cell epitopes are known tomodulate the diversity and spectrum of the
resultant antibody response40. The combination of F1-V immune
complexes and continued release of antigen from nanoparticles
may facilitate the engagement ofmultiple B cells with different recep-
tor specificities that contributed to the diverse epitope recognition
that was observed in this study. Induction of an antibody repertoire
capable of broad epitope recognition is pivotal to developing effi-
cacious vaccines against influenza and HIV that constantly mutate
epitopes to evade the immune response55.
Figure 5 shows how the systems approach proposed herein could be
used to enhance vaccine performance due to a synergistic combination
of several mechanisms provided by each of the platforms that resulted
in the identification of a lead nanovaccine candidate. When translating
these results to humans, the use of aGal-modified immunogens would
result in the formation of antigen-antibody immune complexes that
would promote CD19/CD21-mediated B cell activation, accelerate
memory B cell development, germinal center formation, and antibody
affinity maturation. The use of antigen-loaded amphiphilic nanopar-
ticles would provide sustained release of the antigen, resulting in anti-
gen persistence in vivo and more avid antibodies. The rational choice
of the amphiphilic nanoparticles enables preservation of antigenic
structure and function, which results in enhanced breadth of epitope
recognition by antibodies. Finally, the combination of aGal-modified
antigen and amphiphilic nanoparticles would further enhance APC-T
cell interactions, leading to a more robust cell-mediated immune res-
ponse, which is an important correlate of protective immunity against
several pathogens56,57. In contrast to conventional methods that ‘‘mix
andmatch’’ off-the-shelf antigens and adjuvants, the systems approach
for judicious and concomitant design of novel antigen and adjuvant
technologies that work synergistically can lead to rational design of
efficacious vaccines. This more holistic approach to vaccine design
provides a new paradigm for development of next generation vaccines
against emerging and re-emerging pathogens.
Methods
Materials. Chemicals needed for monomer synthesis and polymerization and
nanoparticle fabrication have been reported elsewhere5,8,9.
Antigenic modification of F1-V. Recombinant F1-V obtained fromNIH Biodefense
and Emerging Infections Research Resources Repository (BEI, Manassas, VA) was
modified by chemical addition of aGal epitopes at lysine residues. Chemical addition
of aGal epitopes was performed at BioProtection Systems Corporation, a subsidiary
of NewLink Genetics Corporation (Ames, IA), using an efficient chemo-enzymatic
synthesis of the aGal trisaccharide and conjugation58. The modified F1-V was
characterized by SDS-PAGE and western blot. aGal-modified and unmodified F1-V
were loaded onto 12% Tris-Glycine pre-cast gels (Bio-Rad Laboratories, Richmond,
Figure 4 | Informatics analysis identified lead candidate vaccine formulation. PCA scores plot of various vaccine regimens. The plot maps out high
dimensional correlations, permitting the tracking of the relative influences of varying the vaccine formulation. The distance along the direction of the red
arrow (i.e., down and to the right) indicates enhancement in immunity following vaccination, and groups that are circled together in blue demonstrated
similar responses.
www.nature.com/scientificreports
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CA), run for 90 min at 100 V, and electro-transferred to a PVDFmembrane for 1 h at
120 V. The membrane was then blocked with 1% fish skin gelatin in Tris-buffered
saline with Tween-20 (TBST) buffer overnight at 4uC. The following day, membranes
were washed three times in TBST and incubated with aGal positive antisera diluted
151,000 in TBST for 2 h. The membrane was then washed and incubated with
alkaline phosphatase conjugated goat anti-mouse IgG diluted in TBST (151,000) for
2 h. Bands were visualized with SIGMA FAST Red TR/Naphthol AS-MX Phosphate
tablets (Sigma Aldrich, St. Louis, MO). Lane 3 in Supplementary Fig. 1 shows that
only bands corresponding to the aGal-F1-V protein were present, further confirming
the successful attachment of aGal epitopes to the protein.
Polymer synthesis and characterization. Synthesis of 1,6-bis(p-
carboxyphenoxy)hexane (CPH) and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane
(CPTEG) diacids was performed as described previously8. Proton NMR and gel
permeation chromatography were utilized to confirm chemical structure and to
measure molecular weight, respectively. The 50550 CPTEG5CPH copolymer had an
average molecular weight of 8,500 Da and a polydispersity index of 1.70, consistent
with previous work5,8.
Nanoparticle synthesis and characterization. F1-V encapsulated nanoparticles were
synthesized by the anti-solvent nanoencapsulation method reported previously11,12.
Scanning electron microscopy (SEM, JEOL 840A, JEOL Ltd., Tokyo, Japan) and
quasi-elastic light scattering (QELS, Zetasizer Nano, Malvern Instruments Ltd.,
Worchester, UK) were employed to characterize particle morphology and size,
respectively. Photomicrographs of F1-V and aGal-F1-V loaded 50550 CPTEG5CPH
nanoparticles (not shown) showed similar spherical morphology and size (147 6
23 nm for F1-V loaded particles versus 1696 16 nm foraGal-F1-V loaded particles),
which was consistent with QELS analysis and with particle morphology and sizes
observed in previous studies6,7,11.
Mice. The a1,3GT gene knockout (KO) mouse model on a BALB/c background was
used to evaluate immune responses to aGal and mimic human immunity to this
epitope. Mice were obtained from BioProtection Systems Corporation (Ames, IA)
and housed under specific pathogen-free conditions where all bedding, caging, and
feed were sterilized prior to use. All animal procedures were conducted with the
approval of the Iowa State University Institutional Animal Care and Use Committee
and were in full compliance with the Committee’s guidelines. Three intraperitoneal
injections of rabbit red blood cells (RRBCs; 3 3 108 RRBCs/injection) were
administered at 14-day intervals to induce production of anti-aGal antibodies. All
RRBC injections were administered prior to immunization with any vaccine
formulations. Seven days after the final RRBC injection, anti-aGal specific serum
antibodies were quantified via ELISA. Only mice with serum optical density values
(OD405 nm) higher than 5X background (PBS) were used in the study; animals were
distributed randomly across the different immunization groups.
Vaccination regimens. Mice were immunized subcutaneously with the regimens
described in Table 1 by suspension in pyrogen-free saline in a volume of 100 mL.
Monophosphoryl lipid A (MPLA) from Salmonella Enterica serotype minnesota Re
595 (Sigma) was used as a control adjuvant at a dose of 10 mg per mouse. A booster
immunization of 5 mg of unmodified F1-V was subcutaneously administered to all
mice 37 days after primary immunization. Blood samples were collected from the left
saphenous vein prior to boost (pre-boost) at day 36. Five days after booster
immunization (day 42), mice were euthanized and serum collected via cardiac
puncture (post-boost). Experiments were performed in quadriplicate with an average
of 6–8 mice per group in each experiment.
Anti-F1-V and anti-LcrV titers. An ELISA method was adapted from a previously
published protocol11,12. Briefly, microtiter plates were coated overnight with 0.5 mg/
mL of F1-V or LcrV (BEI) in phosphate buffered saline (PBS), blocked with 2% (w/v)
gelatin for 2 h and washed with PBS containing Tween-20 (PBS-T). Sera samples
were serially diluted two fold in PBS-T with 1% (v/v) normal goat serum, and
incubated overnight at 4uC. After washing, plates were reacted with alkaline
phosphatase (AP)-conjugated goat anti-mouse IgG (H&L) (Jackson
ImmunoResearch, West Grove, PA) at room temperature for 2 h. Finally, plates were
Figure 5 | Cartoon representation of the systems approach describing a new paradigm for designing next generation vaccines against emerging and re-
emerging pathogens. Specific immune mechanisms are targeted by either the aGal-antigen (blue bubbles), amphiphilic polyanhydride nanoparticles
(green bubbles) or both platforms (yellow bubble). As a result of the synergistic activation of such mechanisms, an augmented and extended antigen-
specific immune response was obtained (purple bubble).
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allowed to react for 20 min at room temperature with phosphatase substrate (Sigma
Aldrich). Optical density (OD) of each well was measured at 405 nm. Endpoint titers
were defined as the highest dilution with an OD value of at least 0.2.
Antibody avidity assay. Antibody avidity analysis was performed as described
previously11,12 by coating plates overnight with 0.5 mg/mL F1-V in PBS. Changes in
OD were measured at 405 nm using a spectrophotometer. Avidity index was defined
as the concentration of NaSCN necessary to reduce the OD by 50% compared to the
wells treated with 0.1 M sodium phosphate.
In vitro CD41 T cell proliferation assay. Antigen specific recall responses were
measured as described elsewhere59. Briefly, a single cell suspension of draining lymph
nodes (brachial and axial) was prepared using a glass tissue homogenizer. Cells were
stained with carboxyfluorescein diacetate succinimidyl ester (CFSE) dye, plated at a
density of 2.5 3 105 cells per well and cultured either in the presence or absence of
10 mg/mL F1-V for four days at 37uC, 5% CO2. Cells cultured in medium alone were
used as negative controls. Following the incubation, cells were harvested, washed,
stained with a PE-Cy7 labeled anti-CD4 antibody, fixed, and acquired on a Becton-
Dickinson FACSCantoTM flow cytometer (San Jose, CA). Data were analyzed using
FlowJo software (TreeStar Inc., Ashland, OR). Data are presented as a stimulation
index, which was calculated by dividing the percentage of CD41 T cells that
proliferated in the presence of F1-V by the percentage of CD41 T cells that
proliferated in the medium alone control.
Statistical analysis. Statistical analysis was performed using JMPH software (SAS
Institute, Cary, NC). For comparisons of multiple vaccine formulations, data were
analyzed using Tukey’s honestly significant difference (HSD) with logarithmic
transformation. Differences were considered significant when p , 0.05.
Epitope mapping by peptide arrays. Two sets of overlapping peptides, one panel
covering the full length of the F1 antigen (27 peptides) and the other covering the full
length of the V antigen (53 peptides), were obtained from BEI. Immunlon 2 HB 96-
well plates were coated with the peptides (5 mg/mL) and incubated overnight at 4uC.
Plates were blocked for 2 h at room temperature with 2.5% skim milk in PBS-T. Sera
samples were diluted 15200 and incubated overnight at 4uC.After three washing steps
with PBS-T, AP-conjugated goat anti-mouse IgG(H&L) at a 151,000 dilution was
added. Plates were allowed to react for 2 h with the phosphatase substrate buffer
described before and changes in OD were determined at 405 nm.
Informatics analysis.Hierarchical clustering.Cluster analysis was used to identify the
peptides for which significantly enhanced immunoreactivity was observed for specific
immunization groups and to compare the responses of the various vaccine
formulations. In this method, the similarity between observations was assessed
according to their relative proximity in the data space. Starting from separate data
points in the parameter space, RN (N5 10 for the comparison of 80 peptides, andN5
80 for 10 different immunization groups), the Euclidean distance, dE, was calculated
to define clusters according to the following equation:
dE~
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
XN
i~1
xi{yi
 2
vuut
The artificial color-coding of a heat map indicated the relative distance among the
data, and the corresponding tree structure, referred to as a dendrogram, showed the
hierarchical grouping.
PCA. PCA was used to mathematically capture differences in properties between
various vaccine formulations. PCA finds ‘‘hidden’’ relationships by describing the
data in a form that reduces inter-correlations. The inputs into the analysis were the
conditions (i.e., antigens and their various formulations) and the outputs were
the biological responses (i.e., titer, avidity, epitope recognition). The data was
decomposed into two plots: the scores plot (Figure 4), which described the conditions
and the loadings plot (Supplementary Figure 3), which described the responses. The
degree of correlation in the results was indicated by proximity; that is, two points with
similar PC values were highly correlated while two points with different PC values
were less correlated.
To compare similarity of conditions to the control, a line drawn through the
control and the origin described the direction of the control, while any distance off
this line was unrelated to the control. The projection (perpendicular) of the various
points onto this line described similarity to the control.
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